Alector said its GSK-partnered antibody missed co-primary clinical endpoints in a Phase III dementia study, producing biomarker changes without corresponding clinical benefit. The company will stop work on the failed asset and cut nearly half its staff as part of a strategic refocus. Leadership changes and a full portfolio review followed the announcement. The failure underscores continued clinical risk in neurodegeneration programs and forced immediate cost and pipeline adjustments.